Hyporesponsiveness to Erythropoietin-Stimulating Agents: Possible Solutions
Almost 80% of dialysis patients have anemia of different severity, with its pathogenesis of multifactorial nature. Relative insufficiency of erythropoietin leading to hyperproliferative erythropoiesis is considered the main underlying cause. Management of anemia has several therapeutic implications,...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/85909 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Hyporesponsiveness to Erythropoietin-Stimulating Agents: Possible Solutions
- Differences in Erythrocyte Index and Hyporesponsiveness to Erythropoiesis in Hemodialysis Patients Treated with Different Erythropoiesis-Stimulating Agents
- Current Anemia Treatment in Hemodialysis Patients: The Challenge for Secure Use of Erythropoietin-Stimulating Agents
- The Protective Role of Erythropoietin in the Developing Brain
- Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients
- rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits
- Pharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease